Extrapleural pneumonectomy for pleural mesothelioma is a surgery that involves removal of the cancerous lung, parts of the diaphragm and nearby tissues where the cancer has spread. The procedure helps some early-stage patients outlive the average one-year prognosis.
The treatment goal of an extrapleural pneumonectomy for mesothelioma is removal of all visible signs of cancer and tissue that may harbor unseen cancerous cells. Even if the cancer returns, the surgery delays recurrence longer than other treatments such as chemotherapy.
While the surgery is not considered a cure, it has helped some patients live longer when combined with other therapies such as chemotherapy, radiation therapy and immunotherapy.
According to a 2018 study published in the European Journal of Cardio-Thoracic Surgery, the extrapleural pneumonectomy helped patients live an average of 33.2 months.
In that study, researchers showed the five-year survival rate was 24.2 percent, a significant improvement to the typical five-year survival rate of less than 10 percent.
The extrapleural pneumonectomy for mesothelioma is also known as an EPP.
An extrapleural pneumonectomy for mesothelioma has the potential to make breathing easier and improve overall quality of life.
Because it removes the majority of the cancer, it may improve a pleural mesothelioma patient’s prognosis, especially if it’s combined with other treatments such as chemotherapy or radiation in what is known as multimodal therapy.
Some studies show patients who undergo an extrapleural pneumonectomy for mesothelioma have a longer survival rate than patients who undergo a pleurectomy and decortication.
In one study led by the late Dr. David Sugarbaker, 70 percent of patients who underwent EPP and other forms of treatment survived up to one year after diagnosis and 48 percent of patients survived at least two years after diagnosis.
Typically, only patients diagnosed with earlier stages of pleural mesothelioma are considered good candidates for the extrapleural pneumonectomy. About 15 to 20 percent of mesothelioma cases qualify for aggressive surgery at the time of diagnosis.
Candidates must also be in otherwise good health with a strong heart. Removal of a lung will increase the workload for the heart and the remaining lung. Doctors assess overall health and assign a performance score. A lower score indicating greater health. Candidates for surgery must have a score no higher than two.
Other tests, such as biopsies, imaging scans and others that assess lung function and heart health, define a patient’s eligibility for the EPP.
Because an EPP is a complicated procedure, an experienced and qualified thoracic surgeon is the only medical professional who should perform it. The entire procedure takes three hours or longer.
Recovery post-extrapleural pneumonectomy is extensive and may require a two-week hospital stay. Generally, the patient is on a respirator for the first couple days or longer and is hooked up to drainage tubes to minimize fluid buildup.
Because complications with this surgery are not uncommon, malignant pleural mesothelioma patients are monitored closely. A heart monitor will constantly evaluate the heart. Blood tests will check for signs of infection, elevated liver enzymes and more.
Nurses will encourage deep breathing and teach coughing techniques to prevent pneumonia. Physical therapists will help patients return to walking and using their arms.
Home recovery from an extrapleural pneumonectomy for pleural mesothelioma begins once the patient is discharged from the hospital. For another six to eight weeks, the patient will be focused on recovery. This includes a lot of rest as the body adjusts to using just one lung to breathe.
At-home recovery may be physically and emotionally difficult. It is important to eat a healthy diet rich in protein and nutrients. Physical therapy and pulmonary rehabilitation therapy help patients recover fully.
Many patients undergo radiation therapy, chemotherapy or both, five or more weeks after surgery. These treatments help to kill cancer cells left behind during surgery. This may delay cancer recurrence.
Patients who qualify for EPP generally qualify for radiation and chemotherapy. Surgery alone doesn’t extend survival as much compared to multimodal therapy. The combination of these treatments offers the greatest hope for longer survival.
New research is investigating other therapies to add to the multimodal approach. For example, clinical trials are researching immunotherapy drugs, gene therapy and photodynamic therapy.
Some EPP side effects, such as fatigue or an infection in the surgical incision, are considered mild and easy to treat. Other complications, such as heart complications and respiratory failure, are considered more serious.
Heart complications include an irregular heartbeat, cardiac hernia and cardiac arrest. Lung complications include respiratory failure, pulmonary embolism, pneumonia and hemothorax (blood collecting in the pleural space). Blood issues include blood clots and internal bleeding.
The surgery has a 3 percent to 8 percent mortality rate, with lower mortality rates at specialty cancer centers with experienced surgeons.
Anatomical changes may occur with the removal of a lung.
At first, most people feel short of breath or may generally feel like they aren’t getting enough air. Breathing techniques and oxygen supplementation help people adjust as the remaining lung learns to compensate for the missing lung.
After recovery from surgery, regular and gentle movement helps the lung expand. Pulmonary rehabilitation may help as well.
People with pleural mesothelioma can determine if this procedure is the right treatment for them by talking to a mesothelioma doctor who specializes in thoracic surgery.
These experts have the training and experience to select the right patients who could benefit from the procedure. Patient selection is not taken lightly by mesothelioma specialists. These experts have the most experience to determine if a patient is the right candidate for such an aggressive surgery.
The pleurectomy and decortication surgery may be the right option for certain early stage patients. This procedure has become the preferred surgery for pleural mesothelioma among many U.S. surgeons because it spares the lung and leaves patients with a higher quality of life.
According to a 2017 study published in the Journal of Surgical Oncology, pleural patients were twice as likely to experience serious complications – including death – in the 30 days following an EPP compared to a pleurectomy and decortication.
However, the rate of local recurrence is higher with a pleurectomy and decortication. This means the cancer has a higher chance of coming back.
10 Cited Article Sources
Sponsored by The Peterson Firm, 1050 30th Street NW, Washington, DC 20007 © 2019 PleuralMesothelioma.com